Insider Ledger
GENB insider buying and SEC filings, explained
Generate Biomedicines, Inc. · CIK 2100782
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$150.3M
Insiders who bought
4
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$16K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 1, 2026 | Planned (10b5-1) | Frances Arnold (Director) sold 1,000 shares at about $16.00 ($16K), marked as a 10b5-1 plan trade. Holdings down <1% to 231,472 shares. | SEC filing Filed Sep 3, 2026 |
| Mar 4, 2026 | Purchase (code P) | Michael Nally (CEO and Director) bought 20,000 shares at $12.00 ($240K), reported as a purchase (code P). Holdings up 4% to 572,707 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Purchase (code P) | Beth Grous (Chief People Officer) bought 300 shares indirectly (by spouse) at $16.00 ($5K), reported as a purchase (code P). New position of 300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Purchase (code P) | Jason Silvers (CFO) bought 2,000 shares indirectly (by child) at $16.00 ($32K), reported as a purchase (code P). New position of 500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Purchase (code P) | Noubar Afeyan (Director and 10% owner) bought 4,687,500 shares indirectly (by entity) at $16.00 ($75.0M), reported as a purchase (code P). Holdings by entity up 11% to 15,264,724 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 7 other reporting owners. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Purchase (code P) | Jane L Mendillo (Director) bought 1,500 shares at $16.00 ($24K), reported as a purchase (code P). New position of 1,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Purchase (code P) | Noubar Afeyan (Director and 10% owner) bought 4,687,500 shares indirectly (by entity) at $16.00 ($75.0M), reported as a purchase (code P). Holdings by entity up 11% to 15,264,724 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 6 other reporting owners. | SEC filing Filed Mar 2, 2026 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
4 insiders bought in 30 days
$150.3M in purchases since Mar 2, 2026 · Purchases traded Mar 2, 2026 to Mar 4, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Noubar Afeyan (Director) | $75.0M | Mar 2, 2026 | SEC filing |
| Jane L Mendillo (Director) | $24K | Mar 2, 2026 | SEC filing |
| Noubar Afeyan (Director) | $75.0M | Mar 2, 2026 | SEC filing |
| Jason Silvers (CFO) | $32K | Mar 2, 2026 | SEC filing |
| Michael Nally (CEO) | $240K | Mar 4, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow GENB in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.